齐湘兵博士 高级研究员，化学中心主任

Xiangbing Qi, Ph.D.

Director of Chemistry Center

National Institute of Biological Science, Beijing

电话： 010--80726688转8655

传真： 010-8070-8048

E-mail:qixiangbing@nibs.ac.cn

Homepage:http://qigroup.nibs.ac.cn/

教育经历

Education

2005-2009年     美国德州大学西南医学中心生物化学系，有机化学博士学位

Ph.D. Organic Chemistry，Department of Biochemistry，University of Texas Southwestern Medical Center at Dallas

2001-2004年     同济大学化学系，有机化学硕士学位

M.S. Organic Chemistry, Department of Chemistry, Tongji University

1997-2001年     济南大学化学化工学院，应用化学学士学位

B.S. Applied Chemistry, School of Chemistry and Chemical Engineering, University of Jinan

工作经历

Professional Experience

2013年- 北京生命科学研究所化学中心主任

Director of Chemistry Center, National Institute of Biological Sciences, Beijing, China

2010-2013年 美国德州大学西南医学中心生物化学系，有机化学与药物化学博士后研究员

Postdoctoral Fellow, Organic Chemistry and Medicinal Chemistry, Department of Biochemistry，University of Texas Southwestern Medical Center at Dallas.

2009-2010年 美国伊利诺伊大学厄巴纳-香槟分校化学系，有机化学博士后研究员

Postdoctoral Fellow, Organic Chemistry，Department of Chemistry，University of Illinois at Urbana-Champaign.

2004-2005年 中科院上海有机所，有机合成/药物研发研究助理

Research Assistant, Organic synthesis/Medicinal chemistry，Shanghai Institute of Organic Chemistry, Chinese Academy of Science.

部分发表文章

Selected Publications

1. Xiangbing Qi*, Wenhui Li*, “Unlocking the secrets to human NTCP structure” The Innovation, 10029

2. Chao Yang, Songlin Bai, and Xiangbing Qi*, “Asymmetric synthesis alkylboranes via enantioselective cross-coupling of gem-Borazirconocene Alkanes”, manuscript in revision.

3. Peihao Chen, Jing Wang, and Xiangbing Qi*, “Total Syntheses of Tetrodotoxin”, manuscript in revision.

4. Xiaolei Liu, Mingliang Lou, and Xiangbing Qi*, “Asymmetric Total Syntheses of Strychnos Alkaloids via Selective Fischer Indolization”，Journal of Organic Chemistry, 2022, 87 (8), 5199-5212

5. Yan Ma*, Yang Cao, Xiaocui Song, Yuanying Zhang, Jing Li, Yankai Wang, Xiaoqing Wu, and Xiangbing Qi, “BAFinder: A software for unknown bile acid identification using accurate mass LC-MS/MS in positive and negative modes”, Analytical Chemistry 2022, 94 (16), 6242-6250

6. Daojiang Yan, Kunya Wang, Songlin Bai, Bingyu Liu, Jian Bai, Xiangbing Qi, Youcai Hu, “Flavin-Dependent Monooxygenase-Mediated 1,2-Oxazine Construction via Meisenheimer Rearrangement in the Biosynthesis of Paeciloxazine” J. Am. Chem. Soc., 2022, 144, 9, 4269-4276

7. Yue Liu, Songlin Bai, Yuanbo Du, Xiangbing Qi*, Hongyin Gao*, “Expeditious and Efficient ortho-Selective Trifluoromethane-sulfonylation of Arylhydroxylamines” Angew. Chem. Int. Ed., 2022, 61, e202115611

8. Gen Li, Mingliang Lou, Xiangbing Qi*, “A brief overview of classical natural product drug synthesis and bioactivity”, Organic Chemistry Frontiers, 2022, 9, 517-571

9. Jie Chen, Nan Liu, Yinpin Huang, Yuanxun Wang, Yuxing Sun, Hong-Wei Wang*, Niu Huang*, Xiangbing Qi* and Xiaodong Wang* “Structure of PDE3A–SLFN12 complex and structure-based design for a potent apoptosis inducer of tumor cells”, Nature Communications, 2021, 12:6204 | https://doi.org/10.1038/s41467-021-26546-8

10. Chao Yang, Chao Jiang, Xiangbing Qi*, “Alkylzirconocenes in Organic Synthesis: An Overview”, Synthesis 2021; 53(06): 1061-1076

11. Zilin Li, Wang Liu, Jiaqi Fu, Sen Cheng, Yue Xu, Zhiqiang Wang, Xiaofan Liu, Xuyan Shi, Yaxin Liu, Xiangbing Qi, Xiaoyun Liu*, Jingjin Ding, Feng Shao* “Shigella evades pyroptosis by arginine ADP-riboxanation of caspase-11”, Nature, 2021,290-295

12. Yang Liu, Lei Zhang, Huan Yan, Zhiqiang Wang, Guoliang Sun, Xiao Song, Zhongmin Zhou,Bo Peng, Liwei Yan, Qingcui Wu, Wenhui Li*, and Xiangbing Qi* “Design of Dimeric Bile Acid Derivatives as Potent and Selective Human NTCP Inhibitors”, J. Med. Chem., 2021, 64 (20), 5973-6007.

13. Lei Zhang, Ye Zhang, Wenting Li, Xiangbin Qi,  “Total Synthesis of (-)-Alstofolinine A through a Furan Oxidation/Rearrangement and Indole Nucleophilic Cyclization Cascade” Angew. Chem. Int. Ed. 2019, https://doi.org/10.1002/anie.201900156.

14. Yu Zhou, Yuanxun Wang, Pengfei Li, Xi-Ping Huang, Xiangbing Qi, Yunfei Du, and Niu Huang. “Exploring Halogen Bonds in 5-Hydroxytryptamine 2B Receptor–Ligand Interactions” ACS Med. Chem. Lett., 2018, 9 (10), pp 1019–1024.

15. Chao Wei, Xiao Han, Danwei Weng, Qiru Feng, Xiangbing Qi, Jin Li & Minmin Luo. “Response dynamics of midbrain dopamine neurons and serotonin Interactions neurons to heroin, nicotine, cocaine, and MDMA” Cell Discovery， 4 : 60 (2018)  1019–1024.

16. Aaron Nash, Xiangbing Qi, Pradip Maity, Kyle Owens, and Uttam K. Tambar*. “Development of the Vinylogous Pictet-Spengler Cyclization and Total Synthesis of (±)‐Lundurine A” Angew. Chem. Int. Ed., 2018, 57, 6888-6891.

17. Rui Lin, Qiru Feng, Peng Li, Ping Zhou, Ruiyu Wang, Zhe Liu, Zhiqiang Wang, Xiangbing Qi, Nan Tang, Feng Shao, Minmin Luo, “A hybridization-chain-reaction-based method for amplifying immunosignals” Nature Methods, 2018 (4), 275

18. Xuekai Zhang, Gang Lu, Meng Sun, Madhu Mahankali, Yanfei Ma, Mingming Zhang, Wangde Hua, Yuting Hu, Qingbing Wang, Jinghuo Chen, Gang He, Xiangbing Qi*, Weijun Shen, Peng Liu, Gong Chen，“A general strategy for synthesis of cyclophane-braced peptide macrocycles via palladium-catalysed intramolecular sp 3 C− H arylation”， Nature Chemistry，2018（10）, 540-548

19. Xueyan Ma, Peixue Li, Peihao Chen, Jinhui Li, Hongling Huang, Chao Wang, Wenjing Li, Jianping Ding, Yun Zhao, Fa-Xing Yu, Xiangbing Qi*, Lei Zhang，“Staurosporine targets the Hippo pathway to inhibit cell growth” Journal of Molecular Cell Biology, 2018, 10, 267-269

20. Yanli Wang, Yuze Sun, Ran Cao, Dan Liu, Yuting Xie, Li Li, Xiangbing Qi*, Niu Huang，“In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery” J. Med. Chem., 2017, 60 (20), pp 8552-8564

21. Shih-Chia Tso, Mingling Lou, Wen-Jun Gui , Cheng-Yang Wu, Jacinta L. Chuang,     Lorraine K. Morlock, Noelle S. Williams, R. Max Wynn, Xiangbing Qi* and David T. Chuang* “Development of Dihydroxyphenyl Sulfonylisoindoline Derivatives as Liver-targeting Pyruvate Dehydrogenase Kinase Inhibitors” J. Med. Chem., 2017, 60 (3), 1142-1150.

22. Yaling Wu, Dingbin Tang, Na Liu, Wei Xiong, Huanwei Huang, Yang Li, Zhixiong Ma,          Haijiao Zhao, Peihao Chen, Xiangbing Qi and Eric Erquan Zhang. “Reciprocal Regulation between the Circadian Clock and Hypoxia Signaling at the Genome Level in Mammals”, Cell Metabolism, 2017, 25 (1), 73-85.

23. Shih-chia Tso^*, Xiangbing Qi^*, Wen-Jun Gui, Jacinta L. Chuang, Lorraine K. Morlock, Amy L. Wallace, Kamran Ahmed, Sunil Laxman, Philippe M. Campeau, Brendan H. Lee, Susan M. Hutson, Benjamin P. Tu, Noelle S. Williams, Uttam K. Tambar, R. Max Wynna, and David T. Chuang. , “Structure-based Design and Mechanisms of Allosteric Inhibitors for Mitochondrial Branched-chain α-Ketoacid Dehydrogenase Kinase.” Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 9728-9733. (* Equal Contribution)

24. Feng Cai, Xiaotao Pu, Xiangbing Qi, Joseph. M. Ready*. “Allenes in Asymmetric Catalysis: Asymmetric Addition of Boronic Acid to α-ketoesters Catalyzed by Allene-Containing Rhodium-Phosphine Catalyst”. J. Am. Chem. Soc., 2011, 133, 18066-18069.

25. Xiangbing Qi, Hongli Bao, Uttam K.Tambar*. “Total Synthesis of (±)-Trigonoliimine C via Oxidative Rearrangement of an Unsymmetrical Bis-Tryptamine”, J. Am. Chem. Soc. 2011, 133, 10050-10053.

26. Hongli Bao, Xiangbing Qi, Uttam K.Tambar*. “Catalytic Enantioselective [2,3]-Rearrangements of Amine N-Oxides ”, J. Am. Chem. Soc. 2011, 133, 1206-1208.

27. Xiangbing Qi, Grant T. Rice, Manjinder S. Lall, Mark S. Plummer, M. Christina White* “Diversification of a β-lactam Pharmacophore via Allylic C–H Amination: Accelerating Effect of Lewis Acid co-catalyst”, Tetrahedron, 2010, 66, 4816-4826.

28. Xiaotao Pu, Xiangbing Qi, Joseph. M. Ready*. “Allenes in Asymmetric Catalysis: Asymmetric Ring Opening of meso-Epoxides Catalyzed by Allene-Containing Phosphine Oxides” J. Am. Chem. Soc. 2009, 131, 10364-10365.

29 Xiangbing Qi, Joseph. M. Ready*. “Synthesis of Cyclopentenones from Cyclopropanes and Silyl Ynol Ethers” Angew. Chem. Int. Ed. 2008, 47, 7068-7070.

30. Xiangbing Qi, Joseph. M. Ready*. “Copper-Promoted Cycloaddition of Diazocarbonyl Compounds with Copper Acetylides” Angew. Chem. Int. Ed. 2007, 46, 3242-3244.

专利Patents

1.    David T. Chuang, Shih-Chia Tso, Xiangbing Qi, Wen-Jun Gui, Cheng-Yang Wu, Jacinta L. Chuang, Uttam K. Tambar, R. Max Wynn “Inhibitors of mitochondrial pyruvate dehydrogenase kinase isoforms 1-4 and uses thereof” US20170001958A1

2.    Wenhui Li, Xiangbing Qi, Huan Yan, Yang Liu, Zhiqiang Wang, Bo Peng, Lei Zhang，“Polymeric Bile Acid Derivatives Inhibit Hepatitis B and D Virus and NTCP Transport”. US20170266206A1。

3.    Niu Huang, Xiangbing Qi, Yanli Wang, Yuze Sun. “Kinase Inhibitors”， WO2017152842A1

4.    Xiangbing Qi, Mingliang Lou, Enlong Wu, Peihao Chen, Qingcui Wu, “Dihydroxyphenyl Sulfonylisoindoline Derivatives”, WO2018095260A1

5.    Erquan Zhang, Xiangbing Qi, Dapeng Ju, Haijiao Zhao, Long Mei, Zhiqiang Wang, Qingcui Wu, “Adenosine Analog and its use in Regulating the Circadian Clock”

PCT/CN2017/071903

化学中心

Chemistry Center

北京生命科学研究所化学中心实验室主要研究方向为具有生物活性的有机小分子合成与药物开发, 天然药物分离纯化与结构分析鉴定，化学小分子库的构建和高通量筛选，天然小分子全合成和生物仿生合成，同时开发新型化学小分子探针用于鉴定药物新靶点并通过探索化学生物学新策略研究小分子与靶点的相互作用关系调控重要的生物学机理。我们实验室还为研究所的各实验室创建高质量的辅助平台,提供专业的化学服务并与生物实验室紧密合作开展前沿交叉课题，基于生物基础研究进展，结合现代药物研发的最新技术手段包括计算机辅助设计以及高通量筛选等，配以先进的仪器装备（NMR，LCMS，HPLC，GC/MS）协助各实验室开发全新的生物医药靶点并通过化学小分子探究与调控重要的生物学途径。我们课题组核心部分主要包括：化学合成实验室，分析检测实验室和高通量筛选实验室。我们将紧密地把有机合成，药物化学，化学生物学与生命科学相结合，从而为北京生命科学研究所建立起一套完善的化学服务与创新型药物研发平台和团队。

In general，the chemistry center provides comprehensive chemical services including: bioactive small molecule synthesis, chemical purification and structure analysis, high-throughput screening (HTS) and lead compound optimization. The center is equipped with several advanced instruments: 400 MHz NMR, preparative LC-MS, UPLC-MS, GC-MS, IR, polarimeter, microwave reactor, and automated HTS facilities. We provide a highly effective and robust platform to conduct professional chemical services and help biological labs to solve challenging biomedical problems. Dr. Xiangbing Qi has been working on the discovery and development of novel small-molecules therapeutics for more than 10 years. The central theme of our research program focuses on the efficient synthesis of bioactive small molecules, High-throughput screening (HTS) for hits validation, hits to lead development, lead optimization as well as the subsequent biological evaluations of these molecules. Assisted by modern techniques such as computer modeling and chemical biology approaches, we collaborate dynamically with various laboratories to identify significant biological targets and facilitate biomedical research for biologically valuable small molecule discovery.